SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop next-generation 10 kV silicon-carbide power semiconductors is drawing attention as a technology-validation milestone. Many traders are bullish on the defense opportunity and potential short covering, while others caution that the prototype awards financial terms are undisclosed and may not translate into near-term revenue.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic equity investment and clinical collaboration around Summits ivonescimab are driving attention, with bullish traders viewing the deal as pharma validation and added funding for development. Others caution that it is not an acquisition and debate whether the investments benefits are already priced in, raising the possibility of a sell-the-news reaction.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software issue that can disrupt automated navigation in a specific landing scenario. Traders disagree over whether the problem is a manageable, previously disclosed glitch or a serious regulatory setback that could prolong certification delays; some view the selloff as overdone, while others cite broader concerns about Boeings execution.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Starship Flight 14 reaching orbit and deploying 26 Starlink V3 satellites is the main focus, with bulls viewing the mission as a step toward expanding Starlink capacity and commercial potential. The reaction is divided: engine trouble shortened the flight and fueled criticism of the mission and the stocks valuation, while supporters call the deployment a major milestone despite the share-price decline.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK study met its primary goals in wet AMD, with Zenkuda and tabirafusp-ted matching Eylea on vision outcomes; Zenkudas six-month dosing durability and a planned FDA filing have fueled a sharp rally. Traders are celebrating the results and squeeze while debating whether the drugs can compete with newer treatments and whether Kodiaks cash needs could lead to dilution, prompting profit-taking and volatility concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Attention centers on the proposed Mesabi Metallics steel complex in Iowa, which traders fear could add competing supply and pressure Cleveland-Cliffs; many question whether the project will secure financing or be completed. Concern about Hamilton production cuts adds to the bearish discussion, while bulls argue the Iowa project is years away and point to strong steel prices.

Aventus Network

AVT is drawing attention after a sharp rally, with traders pointing to breakout momentum and the tokens low float and thin liquidity as factors behind its volatile move. Bulls are urging holders to stay in for a possible continuation, while others are taking profits and questioning whether the gains can hold.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is drawing attention amid a prolonged share-price decline, with traders focused on persistent selling, short interest, and concerns about dilution and insider share sales. The community is split between frustrated holders expecting further downside and buyers who view the weakness as disconnected from SoFis business growth; macro pressure from higher rates also features in the debate.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Goldman Sachs renewed Buy coverage has refocused attention on Amtagvis commercial ramp, with easing launch hurdles and improving margins cited as signs of stronger execution. Traders are broadly optimistic but some question the analysts sharp reversal, while discussion also centers on the overdue revenue-guidance update and upcoming NSCLC data.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERS is drawing attention after a sharp run toward double digits, with traders speculating about large-scale accumulation and sympathy buying after a Phase 3-driven surge in another biotech. Others cite Recorlevs growth and the anticipated XP-8121 Phase 3 program, while cautioning that no new Xeris-specific catalyst is confirmed and that further progress may be needed to sustain the move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS tells clients to consider Asia and Europe as stocks hit new highs

Investing.com -- UBS said in a note Tuesday that investors should broaden their exposure to international equities as U.S. markets continue their upward streak and valuations begin to look stretched.

Earnings replacing tariffs as the primary focus for investors: Barclays

Investing.com -- Investor attention is shifting from geopolitics to corporate fundamentals as earnings begin to eclipse tariffs as the primary market catalyst, according to Barclays.

EU stocks poised for breakout as tariff fears ease: Barclays

Investing.com -- Easing tariff concerns could fuel a breakout in European equities after months of market stagnation, according to Barclays analysts. 

BofA on European earnings: Upside surprise to low expectations

Investing.com -- Second-quarter earnings for European companies have come in ahead of expectations, with financials and U.S.-exposed sectors leading the surprise, Bank of America (BofA) analysts said.

European stocks muted as traders assess earnings, crunch trade talks

Investing.com - European stocks were subdued on Monday, as investors assess a range of corporate earnings and ongoing trade negotiations between the U.S. and the European Union.

Barclays warns: ’Negative summer seasonality’ is looming

Investing.com -- Barclays is warning that markets face “negative summer seasonality,” as August and September typically bring elevated volatility, with policy uncertainty and rising rates adding to investor unease.

Could renewed US fiscal stimulus shield markets from rising tariff risk?

Investing.com -- The potential for near-term U.S. fiscal support may help cushion markets against escalating trade tensions, according to analysts at Bank of America.

BofA survey: Investors more bullish on EU equities, U.S. growth expected to slow

Investing.com -- European fund managers have grown more optimistic about the region’s growth and equities outlook, with a clear tilt away from the U.S. as confidence in its economic momentum wanes, according to Bank of America Securities’ latest monthly survey.

Jefferies downgrades Hermès to “hold” on FX impact, slower growth

STOXX Europe 600: UBS weighs in as index hits its 2025 price target

Investing.com -- The STOXX 600 index has reached UBS’s 2025 price target of 550, prompting the bank to weigh in on the outlook for the region’s equities. UBS strategists reiterated a neutral stance on the index at current levels, but see potential for upside into 2026.

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

STOXX Fundamentals